晚期神经内分泌瘤的药物治疗现状与研究进展  

Current Status and Progress on Drug Therapy for Advanced Neuroendocrine Tumor

作　　者：袁梅琴[1] 朱利明[1] YUAN Meiqin;ZHU Liming(Zhejiang Cancer Hospital,Hangzhou Institute of Medicine(HIM),Chinese Academy of Sciences,Hangzhou 310022,China)

机构地区：[1]浙江省肿瘤医院,中国科学院杭州医学研究所,浙江杭州310022

出　　处：《肿瘤学杂志》2024年第5期371-378,共8页Journal of Chinese Oncology

摘　　要：神经内分泌肿瘤起源于肽能神经元和神经内分泌细胞,临床上可表现从惰性、低度恶性到显著恶性的一系列高度异质的生物学行为。神经内分泌瘤属于分化良好的肿瘤,恶性程度低于神经内分泌癌。晚期神经内分泌瘤多以药物治疗为主。全文就晚期神经内分泌瘤的药物治疗现状及研究进展进行综述。Neuroendocrine neoplasm(NEN) is malignant tumor originated from peptideric neurons and neuroendocrine cells.NEN has significant heterogeneity and clinically manifests a series of biological behaviors from inert,low malignant to prominent malignant.Compared to neuroendocrine carcinoma,neuroendocrine tumor(NET) is a well-differentiated and lower malignancy type of NEN,and drug therapy is the main treatment for advanced NET.This paper reviews the current status and progress on drug therapy for advanced NET.

关 键 词：神经内分泌肿瘤 神经内分泌瘤 生长抑素类似物 靶向治疗 免疫治疗 

分 类 号：R739.4[医药卫生—肿瘤]